Cited by 14Fungal Infections and StudiesAntifungal resistance and susceptibilityActinomycetales infections and treatment

Hospitalized burden and outcomes of coccidioidomycosis: A nationwide analysis, 2005–2012

Open access
Luo, Ruihong, Greenberg, Alan, Stone, Christian D.·2016·Medical Mycology

Abstract

The incidence of coccidioidomycosis (CM) infection has increased over the last 20 years. We investigated recent trends of CM-associated hospitalization in the United States. patients with CM-associated hospitalization were identified from the Nationwide Inpatient Sample, 2005-2012. The outcomes of interest were the trend of annual hospitalization, in-hospital mortality, and independent risk factors for mortality. A total of 30,870 hospitalizations with CM (29,584 of adults; 1,286 of children) were identified. Over the 8-year study period, the number of hospitalizations for CM fluctuated but increased overall with successively higher peaks in 2009 and 2011. The annual median length of stay (LOS) shortened from 6 to 7 days in 2005-2010 to 4 days in 2011 and 5 days in 2012. The inflation-adjusted hospital charges were highest in 2006 then trended down by 21% in 2012. The in-hospital mortality declined from the highest level in 2005 (5.2%) to a low in 2010 (1.1%), then increased modestly in 2011 (1.9%) and 2012 (1.5%). Hospitalizations were identified in 46 states, with nearly half in Arizona (49.1%), followed by California (36.8%), Texas (3.3%), and Nevada (1.6%). Logistic regression analysis in adults revealed that in-hospital mortality was associated with age groups 61-70 years and >70 years (OR = 3.3 and 3.5, respectively. Ref: 18-30 years) and Charlson Index ≥1 (OR = 2.0-8.3). In children, males had lower risk for mortality than females (OR = 0.2). This study shows that CM-associated hospitalizations occur widely throughout the United States with an increasing admission trend; however, patient outcomes have improved and the cost of hospitalization has decreased.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/mmy/myw087

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 20

  1. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infec- tious disease. Emerg Infect Dis. 1996; 2: 192-199.
  2. Litvintseva AP, Marsden-Hauq N, Hurst S et al. Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection. Clin Infect Dis. 2015; 60: e1-3.
  3. Johnson SM, Carlson EL, Fisher FS et al. Demonstration of Coccidioides immitis and Coccidioides posadasii DNA in soil samples collected from Dinosaur National Monument, Utah. Med Mycol. 2014; 52: 610-617.
  4. Petersen LR, Marshall SL, Barton-Dickson C et al. Coccid- ioidomycosis among workers at an archeological site, north- eastern Utah. Emerg Infect Dis. 2004; 10: 637-642.
  5. Turabelidze G, Aqqu-Sher RK, Jahanpour E et al. Centers for Disease Control and Prevention (CDC). Coccidioidomycosis in a state where it is not known to be endemic-Missouri, 2004-2013. MMWR Morb Mortal Wkly Rep. 2015; 64: 636-639.
  6. Sunenshine RH, Anderson D, Erhart L et al. Public health surveillance for coccidioidoycosis in Arizona. Ann N Y Acad Sci. 2007; 1111: 96-102.
  7. Centers for Disease Control and Prevention . Increase in reported coccidioidomycosis: United States, 1998-2011. MMWR Morb Mortal Wkly Rep. 2013; 62: 217-221.
  8. Sondermeyer GL, Lee LA, Gilliss D et al. Epidemiology of pedi- atric coccidioidomycosis in California, 2000-2012. Pediatr In- fect Dis J. 2016; 35: 166-171.
  9. Sondermeyer G, Lee L, Gilliss D et al. Coccidioidomycosis- associated hospitalizations, California, USA, 2000-2011. Emerg Infect Dis. 2013; 19: 1590-1597.
  10. Seitz AE, Prevots DR, Holland SM. Hospitalizations associated with disseminated coccidioidomycosis, Arizona and California, USA. Emerg Infect Dis. 2012; 18: 1476-1479.
  11. Rutala PJ, Smith JW. Coccidioidomycosis in potentially com- promised hosts: the effect of immunosuppressive therapy in dis- semination. Am J Med Sci. 1978; 275: 283-295.
  12. Bercovitch RS, Catanzaro A, Schwartz BS et al. Coccidioidomy- cosis during pregnancy: a review and recommendations for man- agement. Clin Infect Dis. 2011; 53: 363-368.
  13. Peterson CM, Schuppert K, Kelly PC et al. Coccidioidomycosis and pregnancy. Obstet Gynecol Surv. 1993; 48: 149-156.
  14. Charlson ME, Pompei P, Ales KL et al. A new method of classify- ing prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  15. Marsden-Haug N, Goldoft M, Ralston C et al. Coccidioidomy- cosis acquired in Washington State. Clin Infect Dis. 2013; 56: 847-850.
  16. Marsden-Haug N, Hill H, Litvintseva AP et al. Coccid- ioides immitis identified in soil outside of its known range - Washington, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63: 450.
  17. Hector RF, Rutherford GW, Tsang CA et al. The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Resp Public Health. 2011; 8: 1150-1173.
  18. Galgiani JN, Catanzaro A, Cloud GA et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000; 133: 676-686.
  19. Catanzaro A, Cloud GA, Stevens DA et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin In- fect Dis. 2007; 45: 562-568.
  20. Stevens DA, Rendon A, Gaona-Flores V et al. Posaconazole ther- apy for chronic refractory coccidioidomycosis. Chest. 2007; 132: 952-958.

Cited by

Sorted by citations

Authors
Luo, R., Greenberg, A., & Stone, C. D.
Affiliations
Boston University (US)
Corresponding author
Luo, Ruihong
Venue
Medical Mycology
Published
2016-10-04
Volume
55
Issue
4
Pages
myw087
ISSN
  • 0268-1218 (ISSN-L)
  • 1369-3786
  • 1460-2709
OpenAlex
W2529511342
Cited by
14
References
0
Citations by year
2025: 1 · 2024: 3 · 2023: 2 · 2022: 3 · 2020: 3 · 2018: 2
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • Medical Mycology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of General Medical Sciences (P20GM103440)
Topics
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Microbiology › Actinomycetales infections and treatment
Keywords
coccidioidomycosis, hospitalization trends, in-hospital mortality, length of hospital stay, hospital costs, mortality risk factors, Charlson Comorbidity Index, age differences in mortality, children, Arizona, California, Texas, Nevada
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Coccidioidomycosis, Female, Hospitalization, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, United States, Incidence, Survival Analysis, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review